Cita APA (7a ed.)
Biswas, S., Srivastava, Y., Falodia, R., & Hamadttu, A. (2026 Supplement 19). Comparative effectiveness of first-line pembrolizumab plus chemotherapy, nivolumab plus chemotherapy, and nivolumab plus ipilimumab in metastatic esophageal squamous cell carcinoma: A propensity score-matched real-world analysis. Journal of Clinical Oncology, 44, 135-201.
Cita Chicago Style (17a ed.)
Biswas, Shankar, Yashasvi Srivastava, Rahul Falodia, y Ayman Hamadttu. "Comparative Effectiveness of First-line Pembrolizumab Plus Chemotherapy, Nivolumab Plus Chemotherapy, and Nivolumab Plus Ipilimumab in Metastatic Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Real-world Analysis." Journal of Clinical Oncology 44 (2026 Supplement 19): 135-201.
Cita MLA (9a ed.)
Biswas, Shankar, et al. "Comparative Effectiveness of First-line Pembrolizumab Plus Chemotherapy, Nivolumab Plus Chemotherapy, and Nivolumab Plus Ipilimumab in Metastatic Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Real-world Analysis." Journal of Clinical Oncology, vol. 44, 2026 Supplement 19, pp. 135-201.
Precaución: Estas citas no son 100% exactas.